Switch theme
Sign up to access all valuation multiples
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
2020
100
Last FY Revenue n/a
LTM EBITDA -$169M
$2.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
MoonLake has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$169M.
In the most recent fiscal year, MoonLake achieved revenue of n/a and an EBITDA of -$142M.
MoonLake expects next 12-month revenue of XXX and NTM EBITDA of XXX
See MoonLake valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$169M | XXX | -$142M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$170M | XXX | -$143M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$148M | XXX | -$119M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, MoonLake's stock price is $39.
MoonLake has current market cap of $2.5B, and EV of $2.1B.
See MoonLake trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.1B | $2.5B | XXX | XXX | XXX | XXX | $-2.30 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, MoonLake has market cap of $2.5B and EV of $2.1B.
MoonLake's trades at n/a EV/Revenue multiple, and -14.6x EV/EBITDA.
Equity research analysts estimate MoonLake's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MoonLake has a P/E ratio of -16.7x.
See valuation multiples for MoonLake and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.5B | XXX | $2.5B | XXX | XXX | XXX |
| EV (current) | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -12.3x | XXX | -14.6x | XXX | XXX | XXX |
| EV/EBIT | -12.2x | XXX | -14.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -16.7x | XXX | -20.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -17.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMoonLake's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.4M for the same period.
MoonLake's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MoonLake's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for MoonLake and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 37% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MoonLake acquired XXX companies to date.
Last acquisition by MoonLake was XXXXXXXX, XXXXX XXXXX XXXXXX . MoonLake acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was MoonLake founded? | MoonLake was founded in 2020. |
| Where is MoonLake headquartered? | MoonLake is headquartered in United States of America. |
| How many employees does MoonLake have? | As of today, MoonLake has 100 employees. |
| Who is the CEO of MoonLake? | MoonLake's CEO is Dr. Jorge Santos da Silva. |
| Is MoonLake publicy listed? | Yes, MoonLake is a public company listed on NAS. |
| What is the stock symbol of MoonLake? | MoonLake trades under MLTX ticker. |
| When did MoonLake go public? | MoonLake went public in 2022. |
| Who are competitors of MoonLake? | Similar companies to MoonLake include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of MoonLake? | MoonLake's current market cap is $2.5B |
| Is MoonLake profitable? | Yes, MoonLake is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of MoonLake? | MoonLake's last 12 months EBITDA is -$169M. |
| What is the current EV/EBITDA multiple of MoonLake? | Current EBITDA multiple of MoonLake is -12.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
